Investigational drug · Phase 3
CYM-53093
Also called: Navacaprant, NMRA-335140, BTRX-335140
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
0 still active
All registered trials
5
Any phase or sponsor naming "CYM-53093"
First trial start
2023
Sep 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CYM-53093", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder
- Major Depressive Episode Associated With Bipolar II Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Bipolar disorder · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "CYM-53093" as an intervention, largest first.
- Study to Assess the Safety and Effectiveness of NMRA-335140-501Pivotal-lookingTerminated
Neumora Therapeutics, Inc.Industry
NCT06029439 · 904 participants · Start Nov 10, 2023 · Primary completion Aug 17, 2026
Drug: NMRA-335140 · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Phoenix, Arizona; Bentonville, Arkansas · 178 sites in all
- Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderPivotal-lookingCompleted
Neumora Therapeutics, Inc.Industry
NCT06058013 · 430 participants · Start Dec 20, 2023 · Primary completion May 6, 2026
Drug: NMRA-335140; Placebo · For: Major Depressive Disorder
Sites: Encino, California; Garden Grove, California; Los Alamitos, California · 74 sites in all
- Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderPivotal-lookingCompleted
Neumora Therapeutics, Inc.Industry
NCT06058039 · 422 participants · Start Dec 21, 2023 · Primary completion May 4, 2026
Drug: NMRA-335140; Placebo · For: Major Depressive Disorder
Sites: Cerritos, California; Irvine, California; Long Beach, California · 71 sites in all
- Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderPivotal-lookingCompleted
Neumora Therapeutics, Inc.Industry
NCT06029426 · 383 participants · Start Sep 20, 2023 · Primary completion Dec 3, 2024
Drug: NMRA-335140; Placebo · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Phoenix, Arizona; Bentonville, Arkansas · 64 sites in all
Neumora Therapeutics, Inc.Industry
NCT06429722 · 18 participants · Start May 13, 2024 · Primary completion Apr 9, 2025
Drug: NMRA-335140 80 mg; Placebo · For: Major Depressive Episode Associated With Bipolar II Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Garden Grove, California · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Role of PBN-CeA Circuit in Paclitaxel-Induced Neuropathic Pain and Negative Emotions.
Chen H, Chen L, Chen Y, et al. · CNS Neurosci Ther 2026
- Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action.
Repple J, Bayas M, Möser C, et al. · Biol Psychiatry 2025
- Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial.
Mathew SJ, Cutler AJ, Visitacion NC, et al. · J Clin Psychopharmacol 2025
- Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review.
Wong S, Le GH, Vasudeva S, et al. · J Affect Disord 2024
- Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse.
Morrison FG, Van Orden LJ, Zeitz K, et al. · Neuropharmacology 2024
- Opposing Effects on Descending Control of Nociception by µ and κ Opioid Receptors in the Anterior Cingulate Cortex.
Navratilova E, Qu C, Ji G, et al. · Anesthesiology 2024
Also in development for Major Depressive Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- NBI-1065845TAK-653, OsavampatorPhase 35 trials
Neurocrine Biosciences · Major Depressive Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
- CYB003Phase 33 trials
Cybin IRL Limited · Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.